Outlook Therapeutics, Inc. ($OTLK)
Filing Information
| Accession Number | 0000899140-26-000620 |
|---|---|
| Form Type | 4 |
| Filing Date | Jun 2, 2026 |
| Document | View SEC Filing |
Transactions
7
Total Shares
39,516,849
Total Value
$4,999,999.62
P&L
+74.1% (+$3,704,525.76)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Director | Common Stock | โ | May 28, 2026 | Purchase | 8,539,709 | $0.59 | $4,999,999.62 | 22,092,068 | Indirect | See footnote | View Details | |
Director | Warrants (right to buy) | Derivative | May 28, 2026 | Expiration of Long Position | 3,458,571 | โ | โ | 0 | Indirect | See footnote | View Details | |
Director | Warrants (right to buy) | Derivative | May 28, 2026 | Purchase | 3,458,571 | โ | โ | 3,458,571 | Indirect | See footnote | View Details | |
Director | Warrants (right to buy) | Derivative | May 28, 2026 | Expiration of Long Position | 3,458,571 | โ | โ | 0 | Indirect | See footnote | View Details | |
Director | Warrants (right to buy) | Derivative | May 28, 2026 | Purchase | 3,458,571 | โ | โ | 3,458,571 | Indirect | See footnote | View Details | |
Director | Warrants (right to buy) | Derivative | May 28, 2026 | Expiration of Long Position | 8,571,428 | โ | โ | 0 | Indirect | See footnote | View Details | |
Director | Warrants (right to buy) | Derivative | May 28, 2026 | Purchase | 8,571,428 | โ | โ | 8,571,428 | Indirect | See footnote | View Details |